GMED
HealthcareGlobus Medical, Inc. · Medical - Devices · $11B
What is Globus Medical, Inc.?
Globus Medical is a large-cap medical device company focused on musculoskeletal health. Operating from Audubon, Pennsylvania, it serves patients across the United States and internationally with a broad portfolio spanning spine, orthopedic trauma, and joint reconstruction.
Globus Medical develops, manufactures, and commercializes implants and instruments for treating musculoskeletal disorders. Revenue comes primarily from direct sales to hospitals and surgical centers through a specialized sales force. The company addresses conditions ranging from spinal degeneration and deformity to orthopedic trauma and joint deterioration. It also distributes regenerative biologic products and human tissue-based solutions, positioning itself as a comprehensive musculoskeletal platform rather than a single-category device maker.
Globus Medical was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
- Spine fusion implants including pedicle screw systems and intervertebral spacers
- Motion preservation technologies such as total disc replacement devices
- Interventional pain management solutions for vertebral compression fractures
- Orthopedic trauma products including intramedullary nails and fracture plates
- Hip and knee joint reconstruction implants and arthroplasty systems
Is GMED a Good Stock to Buy?
UQS Score rates GMED as Good overall, reflecting a balanced profile across its five evaluation pillars.
Risk stands out as the strongest pillar, suggesting the business carries a relatively conservative financial structure compared to many healthcare peers. Growth and Quality both register as Good, pointing to a company that has demonstrated meaningful expansion while maintaining reasonable operational standards. Valuation also lands in Good territory, meaning the stock does not appear significantly stretched relative to its fundamentals.
The Moat pillar is rated Weak, indicating that durable competitive advantages — such as pricing power or switching costs — are less clearly established than at some sector peers.
Pro members can view the complete pillar breakdown and underlying financial metrics behind each GMED rating. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does GMED pay dividends?
No — Globus Medical, Inc. does not currently pay a dividend.
Globus Medical does not currently pay a dividend. For a growth-oriented medical device company, this is common — capital is typically reinvested into product development, clinical studies, and geographic expansion rather than returned to shareholders as income. Investors seeking yield would need to look elsewhere, but those focused on long-term capital appreciation may find the reinvestment approach aligned with their goals.
When does GMED report earnings?
Globus Medical reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
The company's Good Growth pillar rating suggests it has delivered meaningful revenue and earnings progress in recent periods. Its Strong Risk profile indicates results have been achieved without excessive financial leverage or volatility. Trends in spine procedure volumes and orthopedic trauma demand tend to be key drivers of quarterly outcomes.
For the most recent quarter's results and guidance, visit Globus Medical's investor relations page directly.
GMED Price History
+30.2% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Globus Medical, Inc.?
Based on Globus Medical, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
GMED Long-term Outlook
Globus Medical's Good Growth pillar points to a business with credible expansion potential, supported by aging demographics and rising demand for musculoskeletal procedures globally. The Strong Risk pillar suggests the company is well-positioned to navigate near-term uncertainty without significant balance sheet stress. However, the Weak Moat rating is a meaningful consideration — without deeply entrenched competitive advantages, sustaining above-average growth margins over a long horizon may prove challenging if larger rivals intensify competition.
Growth drivers
- Aging global population driving higher volumes of spine and joint procedures
- Expansion of the orthopedic trauma and joint reconstruction product lines
- International market penetration beyond the core US business
Key risks
- Limited moat may expose pricing to pressure from larger, better-resourced competitors
- Healthcare reimbursement changes could affect procedure volumes and device pricing
- Integration complexity following recent acquisitions could weigh on near-term execution
GMED vs Peers
Globus Medical operates in a competitive medical device landscape alongside companies addressing different aspects of interventional and reconstructive care.
Penumbra focuses on neurovascular and neuro-critical care devices, competing in adjacent interventional markets rather than spine or orthopedic reconstruction.
Align Technology addresses dental and orthodontic alignment, representing a distinct musculoskeletal niche with a strong consumer-facing brand component.
Insulet operates in diabetes management through wearable insulin delivery systems, competing for healthcare capital allocation rather than direct procedure overlap.
Frequently Asked Questions
What does Globus Medical do?
Globus Medical develops and sells medical devices for patients with musculoskeletal disorders. Its products cover spinal fusion, motion preservation, orthopedic trauma fixation, and hip and knee joint reconstruction. The company also distributes regenerative biologic products and human tissue-based solutions to hospitals and surgical centers across the US and internationally.
Does GMED pay dividends?
Globus Medical does not currently pay a dividend. The company reinvests available capital into product development, clinical expansion, and geographic growth. Investors seeking regular income distributions would need to consider other options, as GMED is structured more as a growth-oriented medical device business.
When does GMED report earnings?
Globus Medical follows a standard quarterly earnings cadence for US-listed companies. Specific dates are announced in advance through the company's investor relations page, which is the most reliable source for upcoming report schedules and conference call details.
Is GMED a good stock to buy?
UQS Score rates GMED as Good overall. The Risk pillar is Strong, and both Growth and Quality are rated Good, which suggests a reasonably well-run business with expansion potential. The Weak Moat rating is a consideration for investors focused on long-term competitive durability. The full pillar breakdown is available to Pro members.
Is GMED overvalued?
GMED's Valuation pillar is rated Good, suggesting the stock is not significantly overpriced relative to its fundamentals at the time of scoring. Valuation assessments can shift with market conditions and earnings revisions, so reviewing the full metrics behind the rating is worthwhile. Pro members can access the detailed valuation analysis.
How does GMED compare to its competitors?
Globus Medical competes broadly in the medical device space alongside companies like Penumbra, Align Technology, and Insulet. Each addresses different clinical categories — from neurovascular care to dental alignment and diabetes management. GMED's differentiation lies in its comprehensive musculoskeletal platform spanning spine, trauma, and joint reconstruction.
What is GMED's market cap bracket?
Globus Medical is classified as a large-cap company. This places it among the more established players in the medical device sector, with the scale to support a broad product portfolio, dedicated sales infrastructure, and ongoing investment in research and development.
Who founded Globus Medical?
Globus Medical was incorporated in 2003. Founding and leadership history is publicly documented through the company's official filings and investor relations materials, which provide the most accurate and detailed account of its origins and executive team.
Is GMED a long-term quality investment?
From a quality indicator perspective, GMED's Strong Risk pillar and Good ratings across Quality and Growth suggest a business with meaningful long-term characteristics. The Weak Moat rating is worth monitoring, as competitive advantages are a key factor in sustaining performance over extended periods. The full analysis is available to Pro members.
What is the main competitive advantage of Globus Medical?
Globus Medical's breadth across spine, trauma, and joint reconstruction gives it a broad commercial footprint in musculoskeletal care. However, its UQS Moat pillar is rated Weak, indicating that deeply entrenched advantages — such as strong pricing power or high switching costs — are less clearly defined compared to some peers in the broader healthcare sector.
What sector does GMED belong to?
Globus Medical operates in the Healthcare sector, specifically within the medical devices industry. It focuses on musculoskeletal solutions, which places it in a segment driven by surgical procedure volumes, aging demographics, and ongoing innovation in implant design and minimally invasive techniques.
Is GMED a growth stock or value stock?
Based on UQS pillar ratings, GMED shows characteristics of both. The Good Growth pillar reflects meaningful expansion potential, while the Good Valuation pillar suggests the stock is not priced at a steep premium. This combination may appeal to investors looking for growth without paying an extreme valuation multiple.
Unlock Full GMED Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access underlying financial metrics driving each pillar
- ✓Compare GMED against sector peers on quality and risk
- ✓Track valuation changes as new data is published
- ✓Screen for similar large-cap healthcare opportunities
- ✓Get the complete analyst-grade view in one dashboard
Pro Analysis
GMED — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 64.2 | 67.2 | 36.0 | 74.9 | 82.4 | 74.0 | -1.0 |
| May 13, 2026 | 65.2 | 68.5 | 36.0 | 74.4 | 82.4 | 78.7 | +0.2 |
| May 12, 2026 | 65.0 | 68.3 | 36.0 | 74.4 | 82.4 | 77.8 | +3.5 |
| May 7, 2026 | 61.5 | 63.3 | 36.0 | 71.4 | 82.4 | 66.8 | 0.0 |
| May 3, 2026 | 61.5 | 63.3 | 36.0 | 71.4 | 82.4 | 67.0 | +0.2 |
| Apr 26, 2026 | 61.3 | 63.3 | 36.0 | 71.4 | 82.4 | 65.7 | 0.0 |
| Apr 25, 2026 | 61.3 | 63.3 | 36.0 | 71.4 | 82.4 | 65.6 | 0.0 |
| Apr 23, 2026 | 61.3 | 63.2 | 36.0 | 71.4 | 82.4 | 65.7 | -0.1 |
| Apr 19, 2026 | 61.4 | 63.2 | 36.0 | 71.4 | 82.4 | 66.4 | -0.1 |
| Apr 18, 2026 | 61.5 | 63.2 | 36.0 | 71.4 | 82.4 | 67.3 | -0.9 |
GMED — Pillar Breakdown
Quality
— 67.2/100 (25%)Globus Medical, Inc. shows solid profitability with healthy returns on capital and reasonable margins.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 74.9/100 (20%)Globus Medical, Inc. demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 82.4/100 (15%)Globus Medical, Inc. carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 73.6/100 (15%)Globus Medical, Inc. trades at a reasonable valuation with decent earnings yield and FCF multiples.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 36/100 (25%)Globus Medical, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for GMED.
Score Composition
Financial Data
More Stock Analysis
How is the GMED UQS Score Calculated?
The UQS (Unified Quality Score) for Globus Medical, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Globus Medical, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Globus Medical, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.